Mikhail Blagosklonny is an Oncology professor at the Rosewell Park Cancer Institute. He discovered the healing properties of Rapamycin. He believes it can be used to increase the life expectancy of cancer patients. He has conducted extensive research in the realm of cancer therapy. As Editor-in-Chief of Oncotarget, he conducted research on aging people. As a result, his contribution to the treatment of cancer is phenomenal.
What is Rapamycin?
Traditionally the drug was used for organ transplants. It would decrease the patient’s chances to reject the organ. In the early 1970’s it was discovered that the drug had tremendous immunosuppressive and antiproliferative properties. Although, the drug is an immunosuppressive drug it is less toxic toward the kidneys. Unlike other immunosuppressive drugs that ultimately leads to kidney failure.
Hemolytic-uremic syndrome is characterized as anemia, kidney failure, and low platelet count. The only cure for this disease is to get a kidney transplant. Without rapamycin, the new kidney will contract the disease. However, rapamycin reduces the chance of the kidney toxicity. Dr. Blagosklonny discovered the drugs ability to rejuvenate the immune system in elderly patients. The progress was noted after administering the influenza vaccine to them. This study also discovered the drug helped mice to live with tuberculosis. Although his discoveries are inconclusive in expanding human life, he continues to study.
Treatment of LAM
Rapamycin is a wonder drug that aids in the treatment of LAM patients. This disease is most noted for causing a rare lung disease in childbearing age women. However, rapamycin is the primary drug of choice to cure this disease. Its also used as a coronary stent covering. Rapamycin is applied to the stent after the balloon angioplasty is done. It’s the drug of choice because it doesn’t have to be reapplied often for it be effective.
Rapamycin treatment for Lupus
This drug is crucial in the treatment of Lupus Erythematosus. The disease has left patient’s resistance to immunosuppressant drugs. However, rapamycin unblocks mTORC1 in the patient. Thus, the patient body accepts the drug leading us closer to finding a cure.
Contributions to Oncology
Dr. Blagosklonny contributions to the field of Oncology is unprecedented. He’s not only a researcher but an expert in his field. He continues to seek out why cancer is prevalent among the elderly population. His quest is complex yet morally good. He seeks to treat the clients safely and effectively. His passion and dedication in oncology treatment encourage his students and peers to further his work. He is greatly respected by his students and colleagues
His goal is to not only treat patients with cancer but its to eradicate cancer cells. In hopes of finding a cure for cancer. He aspires to treat patients effectively without making them sick. He continues to conduct and gather research to cure cancer. He is determined to discover the connection between elderly people and cancer. His research is a great contribution to science. He desires to treat the patient in an economically feasible manner.
There has been a significant increase in the establishments of government cancer research centers all over the world, this is due to a continued surge in the number of people developing this deadly disease. The aim of establishing these centers mainly is to conduct various experiments that would eventually lead to the finding of a cure. In regards to this, many private research centers are also cropping up to take on this task of also finding a treatment for cancer. One good example of such a cancer research facility is Seattle Genetics that was started by Dr. Clay Siegall way back in 1998.
This research center has for many years been responsible for developing of various types of medications used in the treatment of a number of diseases. All these medications have been developed and carefully tested and approved by the FDA
for use by the public. One good example of such a drug that was produced by the Seattle Genetics research center is the first ever antibody drug conjugate. This was developed under the watchful supervision of Dr. Clay Siegall and was later approved by the FDA. The research facility also boasts on more than twenty now being used for treatment with other drugs undergoing medical trials and development.
Dr. Siegall interest in medicine and research sparked when he was a little boy and this motivated him to pursue a science course in Maryland University (Zoology).Dr. Clays’ educational background also saw him earn his Ph. D in genetics at George Washington University.
When still in his first year of his undergraduate study at the University sad news reached him about a member of his family being diagnosed with melanoma. What made him sad the most was the ruthless and painful measures that were used while treating the disease. This awakened his childhood interest in medicine and research and as fate would have it he landed himself in the field of oncology a few years later. This became his new-found home as he now dedicated his time, resources and energy towards developing better and new ways of performing cancer therapies and never losing the hopes of one day finding a cure.
Therefore, it is worth acknowledging that Dr. Clay Siegall has played a very pivotal role in the transformation of how cancer therapies are done. He has also aided in improving the quality of these treatments used while reducing the effects they have on patients.